Funding for this research was provided by:
Merck (MISP #39207)
Bristol-Myers Squibb (CA814-184)
Adaptive Biotechnologies (UPCI 11-063)
Text and Data Mining valid from 2018-10-23
Received: 31 July 2018
Accepted: 10 October 2018
First Online: 23 October 2018
Ethics approval and consent to participate
: The study was initiated after approval from the institutional review board (IRB) and was conducted in accordance with the Declaration of Helsinki. A University of Pittsburgh IRB approved written informed consent (IRB# PRO12020161) was obtained from all patients.
: Not applicable.
: Dr. Tarhini received research grant support Merck, Bristol Myers Squibb and Adaptive Biotechnologies. Dr. Tarhini served as a consultant for Merck, Bristol Myers Squibb, HUYA, Pfizer, Sanofi Genzyme, Novartis, Genentech-Roche, Array Biopharma, NewLink Genetics. John M Kirkwood declared consulting or advisory role to BMS, Merck, Novartis, Roche, Genentech, EMD Serrono, Array Biopharma, Prometheus. Erik C. Yusko and Julie A. Rytlewski are employees or Adaptive Biotechnologies. The rest of the authors declare no potential conflicts of interest relevant to the study.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.